Palisade Bio
PALI
5 hedge funds and large institutions have $1.94M invested in Palisade Bio in 2018 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
6% more capital invested
Capital invested by funds: $1.83M → $1.94M (+$114K)
0% more funds holding
Funds holding: 5 → 5 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$156K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$39K |
| 2 |
Fifth Third Bancorp
Cincinnati,
Ohio
|
-$16K |
PALI Hedge Fund Activity: Q1 2018 in Review
5 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q1 2018, worth a combined $1.94M — up 6.2% from $1.83M a quarter earlier.
Fund positioning in PALI was balanced in Q1 2018: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, adding an estimated $156K. The largest seller was Jane Street, cutting an estimated $39K.
- 5 institutional investors held Palisade Bio (PALI) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $1.94M of Palisade Bio stock for Q1 2018, up 6.2% quarter-over-quarter.
- 0 funds opened new Palisade Bio positions in Q1 2018 and 0 closed out.
- The largest Palisade Bio buyer in Q1 2018 was Vanguard Group, an estimated $156K added.
- The largest Palisade Bio seller in Q1 2018 was Jane Street, an estimated $39K sold.
Based on aggregated 13F filings for Q1 2018.